Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
View/ Open
Author
Nazha, Aziz
Sekeres, Mikkael A.
Komrokji, Rami
Kantarjian, Hagop
Roboz, Gail
Fenaux, Pierre
Prebet, Thomas
Azarnia, Nozar
Zbyszewski, Patrick S.
Fruchtman, Steven M.
Santini, Valeria
Silverman, Lewis R.
Platzbecker, Uwe
Garcia-Manero, Guillermo
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/s41408-017-0018-7Metadata
Show full item recordCitation
Nazha, A., M. A. Sekeres, R. Komrokji, D. P. Steensma, H. Kantarjian, G. Roboz, P. Fenaux, et al. 2017. “Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.” Blood Cancer Journal 7 (12): 644. doi:10.1038/s41408-017-0018-7. http://dx.doi.org/10.1038/s41408-017-0018-7.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802598/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014421
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)